$ZCAR

Zoomcar Holdings, Inc. 1Q 2026: Revenue $2.35M, EPS $(0.24) — 10-Q Summary

Zoomcar Holdings reported 1Q 2026 revenue of $2.35M, up 2% year over year, but a larger net loss attributable to common stockholders of $5.37M versus $4.21M. Diluted EPS was a loss of $0.24 versus $0.50. The company cited lower booking days and cost reductions, and said it expects cash constraints and additional financings.

Original reporting
Published Aug 14, 2026, 7:41 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Zoomcar Holdings, Inc. 1Q 2026: Revenue $2.35M, EPS $(0.24) — 10-Q Summary — source image
Decision brief

The 30-second read

$ZCARBearishMed
01

Why it matters

Traders can use the disclosed quarterly metrics and the stated expectation of additional financings to reassess dilution risk and near-term downside catalysts (capital raise timing).

02

Market read

A small-cap earnings-style filing update with explicit liquidity and loss trajectory details, likely to influence positioning around dilution and funding risk.

03

What to watch

The summary notes lower gross booking value and declining booking days, which may be more important than the headline revenue growth for near-term demand expectations.

Relevance 6/10Novelty 5/10Timing: today’s 10-Q filing summary (Aug. 14, 2026)

Background

The piece is a brief summary of Zoomcar’s 1Q 2026 10-Q, focusing on revenue, losses, bookings, cost optimization, and liquidity outlook.

Company-level read

Ticker impact

$ZCARBearishMedium confidence
Context

Zoomcar reported 1Q 2026 revenue of $2.35M and a wider net loss, plus management expects ongoing cash constraints and additional financings.

Expected impact

Near-term downside bias as investors price in continued cash burn and potential dilution, despite cost reductions.

Evidence & confidence

The article provides concrete quarterly financials (revenue, net loss, EPS) and an explicit liquidity outlook (additional financings), both directly relevant to risk and capital structure expectations.

Market effects

Reinforces the funding and profitability challenge for asset-light mobility/booking platforms relying on bookings and dynamic pricing.

No specific regional impact stated.

Limited, company-specific liquidity and loss trajectory.

Counterpoint

Cost-of-revenue reduction (38%) and modest revenue growth could indicate operating leverage if bookings stabilize.

Key entities

  • Zoomcar Holdings, Inc.

    Reported 1Q 2026 revenue of $2.35M, wider net loss, and expects additional financings due to cash constraints.

Related articles

$ZCARMed

Zoomcar Cuts Fiscal 2026 Net Loss as Profitability Metrics Improve (ZCAR)

Zoomcar Holdings reported fiscal year ended 31 March 2026 net loss attributable to shareholders fell 43% to $14.62M, with adjusted EBITDA loss down 47% to $5.22M. Revenue was roughly flat at $9.16M. Contribution profit rose 19% to $5.07M. Bookings fell 8% to 391,302 as marketing spend was reduced. The company is raising growth capital, running a warrant exchange, and evaluating a U.S. uplisting.

$SPGMedAI 8/10

Why Simon Property Group’s malls are attracting more retailers

Simon Property Group reported strong Q2 results with revenue up 20% to $1.79B. CEO Eli Simon noted high retailer demand, 1,200 leases signed, and 17% positive rent spreads. Portfolio occupancy remained at 96%, with re-leased Saks Off 5th space expected to yield higher rents. FFO was flat at $1.185B, while net income decreased 13.1% to $483.1M. Sales productivity rose 14% to $838 per sq ft.

$GILDHighAI 8/10

Gilead’s Core Business Is Accelerating, But Will Its $11 Billion Pipeline Bet Pay Off?

Gilead Sciences (GILD) reported Q2 2026 with double-digit growth in commercial portfolio sales, but posted a significant loss due to $11.2B in R&D expenses from acquisitions. HIV sales rose 12% to $5.7B, while non-HIV areas like liver disease and cancer treatments also showed growth. The company raised its 2026 sales guidance and made strategic acquisitions, but faces risks from clinical development and financial obligations.

$ABBVMedAI 8/10

AbbVie’s Humira Replacement Strategy Is Working, But Could Growth Be Too Concentrated?

AbbVie (NYSE:ABBV) reported Q2 2026 revenue of $16.99B, up 10.2%, driven by immunology and neuroscience. Skyrizi and Rinvoq revenues grew 24.4% and 24.5% respectively, offsetting Humira's 35.9% decline. However, concentration risk exists as these two products made up 47% of revenue. Oncology and aesthetics showed weaker performance, with oncology revenue down 1.5%. Adjusted EPS rose 22.9% to $3.65.